summary 1. Studies with a sensitive radioenzymatic assay for plasma noradrenaline suggest there is a selective overactivity of the sympathetic nervous system in essential hypertension.
plasma catecholamines it has been demonstrated that plasma noradrenaline concentration and dopamine-b-hydroxylase activity are elevated in patients with essential hypertension (Louis, Doyle, Anavekar, Johnston, Geffen & Rush, 1974) . These results suggest that essential hypertension is associated with sympathetic overactivity. Moreover, this increased sympathetic drive must be selective as it is not associated with increased heart rate, cardiac output, plasma renin and other sympathetic functions and presumably selectively involves resistance blood vessels.
It seems, however, that the excess sympathetic drive is not by itself able to sustain the level of blood pressure seen in many patients with essential hypertension. Studies in normotensive subjects, and in patients with essential hypertension and in patients with depression (Louis, Doyle & Anavekar, 197% indicated that eighteen of forty-four patients with essential hypertension had plasma noradrenaline levels in the normal range and an elevated mean blood pressure. In view of the complex release and inactivation mechanisms present at the nerve ending for noradrenaline. it could be argued that spill-over of noradrenaline into the plasma only occurs in the presence of a considerable increase in transmitter release. In addition the excess sympathetic drive may be acting in the presence of some other factor, perhaps causing a hyper-reactivity of blood vessels to pressor amines which augments its effect. This would be consistent with the idea that the level of blood pressure in man reflects both autonomic and nonautonomic components (Korner, Shaw, Uther, West, McRitchie & Richards, 1973 
Serotonin
One additional peripheral factor which may be important is serotonin. There is considerable evidence that serotonergic neurons in the central nervous system are involved in the maintenance of vascular tone (Tabei, Spector, Louis & Sjoerdsma, 1969; Wing & Chalmers, 1974; Jarrott, McQueen, Graf & Louis, 1975a) .
However, serotonin may also have a peripheral role in regulating vascular tone as was originally suggested by Page & McCubbin (1954) . Serotonin receptors have been demonstrated in some blood vessels (Page, 1954) and other studies report that in genetic hypertensive rats and rats with deoxycorticosterone acetate-salt hypertension, some blood vessels (for example, mesenteric vessels) are supersensitive to serotonin (McGregor & Smirk, 1970; Haeusler & Finch, 1972) . Studies in the rat indicated that the turnover of serotonin in the aorta was 247 ng h-g-and in the mesenteric artery 303 ng h-g-I , which is approximately twice the reported turnover for noradrenaline. In other unpublished studies we have demonstrated serotonin in the blood vessels of the chicken, rabbit and man. Moreover, administration of the serotonin synthesis inhibitor p-chlorophenylalanine or the a-methylserotonin precursor a-methyl-5-hydroxytryptophan lowers blood pressure in experimental hypertension (Tabei et al., 1969; Jarrott et al., 1975a) .
It is not clear in the rat whether the serotonin is present in the blood vessel wall or only in surrounding mast cells. However, serotonin was still detected in blood vessels after careful microdissection of the adventitia, suggesting that some serotonin is in the vessel wall. In either case it is possible to propose a vascular action for peripheral serotonin. In the rat, the mast cells are in such close proximity to the arteriolar wall and its adrenergic innervation (Furness, 1973 ) that they could easily influence vasoconstrictor tone, and even be under indirect autonomic control. For example, it has been demonstrated that endogenous substances such as ATP (Diamant & Kruger, 1967) , prostaglandins and noradrenaline, which are known to be released during sympathetic activity (Hedqvist, 1973) , will release serotonin from mast cells (Ladd & Chahl, 1974) and these substances could be a stimulus for the release of serotonin.
These results therefore raise the possibility that peripheral vasoconstriction by serotonin may be an important component of blood pressure maintenance.
Sympathetic drive
The nature of the increased sympathetic drive has not yet been resolved. Either an increased central sympathetic drive or a local disturbance in nerve endings in which a normal firing rate releases abnormal amounts of transmitter could explain the suggested increase in sympathetic drive. There is considerable evidence that normal vascular tone is regulated by a vasomotor centre in the brain stem and this area has noradrenergic and serotonergic pressor and depressor inputs (Wing & Chalmers, 1974) . Attempts have been made to develop methodology which allows the study of local sympathetic turnover in central nervous system nuclei and peripheral blood vessels (Axelrod, 1975 ; Jarrott, Tomlinson & Louis, 1975b) . This approach has been used to study the non-innervated sympathetic tumour phaeochromocytoma (Jarrott et al., 1975b) , and it is suggested that similar studies of local regulating mechanisms of neurotransmitter release would be valuable in other forms of hypertension.
Phaeochromocyroma
Tyrosine hydroxylase, dopa decarboxylase and dopamine-/?-hydroxylase activities were measured in six phaeochromocytomas and in human adrenal glands and found to be three to ten times higher in phaeochromocytomas than in adrenal glands. On the other hand, the activity of monoamine oxidase in phaeochromocytomas was only 25% of normal activity. Since the enzyme monoamine oxidase is localized intracellularly in mitochondria, succinate dehydrogenase activity (a mitochondria1 marker) was also measured and found to be reduced. This suggests a reduced number of, or severe damage to, mitochondria in the tumour cells. Mitochondria1 damage was confirmed on electron microscopy (Watanabe, Burnstock, Jarrott & Louis, 1976) .
The elevated activities of tyrosine hydroxylase, dopa decarboxylase and dopamine-/?-hydroxylase in the tumours could explain the increased rates of synthesis and levels of catecholamines compared with adrenal glands. The reduced monoamine oxidase activity of tumours is of interest since this enzyme is believed responsible for breaking down excess 'free' noradrenaline in the cytoplasm, and its deficiency would enable newly synthesized noradrenaline to by-pass the saturated vesicle stores and diffuse out of the tumour cell into the circulation.
Role of hormones in pathogenesis of hypertension
These data therefore support the suggestion that the hypertension in phaeochromocytoma results from excessive (adrenal) synthesis of catecholamines that by-pass the normal storage and secretion mechanism and diffuse into the circulation (Fig. 1) . The results may explain some of the clinical features of the disease phaeochrornocytorna, as well as the provocative actions of vasodilator agents such as histamine and glucagon in doses that do not release catecholamines from the adrenal medulla (Geffen, Rush, Louis & Doyle, 1973) .
More importantly, the studies in phaeochromocytoma indicate the importance of local regulatory mechanisms in neurotransmitter release and show the need for similar studies in other forms of hypertension. Thus, in some circumstances, similar local defects in adrenergic neurons might give rise to elevated blood pressures independently of an increased sympathetic drive, whereas if they occurred in adrenergic neuron and nerve terminals in the central nervous system they might explain the increased central drive which it is suggested occurs in essential hypertension.
